Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorinostat + lenalidomide + dexamethasone
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Vorinostat + lenalidomide + dexamethasone is a combination therapy investigated primarily for the treatment of relapsed or refractory multiple myeloma. Vorinostat is a small molecule inhibitor of class I and II histone deacetylases (HDACs), which modulates gene expression and induces cell cycle arrest, differentiation, and apoptosis in malignant cells. Lenalidomide is an immunomodulatory agent structurally related to thalidomide that exerts anti-myeloma effects through direct tumoricidal activity, inhibition of angiogenesis, and modulation of the immune microenvironment. Dexamethasone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties that also induces apoptosis in certain hematologic malignancies. Preclinical studies suggest synergy between these agents due to their distinct but complementary mechanisms of action. Clinical trials have demonstrated that this combination can be effective and generally well-tolerated in patients with relapsed or refractory multiple myeloma[1][2][3][4][5][6].
- Other names
- Vorinostat-Lenalidomide-DexamethasoneSAHA + lenalidomide + dexamethasone
02
Targets
CRBN (Cereblon)GR (Glucocorticoid receptor)HDAC1 (Histone Deacetylase 1)HDAC2 (Histone deacetylase 2)
Beyond the preview
Go deeper on vorinostat + lenalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorinostat + lenalidomide + dexamethasone.